Ulcerating haemorrhagic colitis induced by celecoxib;Colite aiguë ulcéro-hémorragique induite par le célécoxib

Presse Medicale

Volumn 34, Issue 6, 2005, Pages 443-445

  Rey, Philippe ^a,d   Andriamanantena, D ^a   Carrere C ^a   Casassus Builhe D ^a   Hamant, N ^b   Perret, J L ^c  

^a Hop Instruction des Armees Legouest   (France)

^b Centre de pathologie   (France)

^c Fedration de Medecine   (France)

^d Service des Maladies Digestives   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC COLITIS; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; ISCHIALGIA;

EID: 16444368621     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)83940-5     Document Type: Article

References (15)

1. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-33.
2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study. A randomised controlled trial. JAMA 2000; 284: 1247-55.
3. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C et al. COX-1 and COX-2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002; 122: 1913-23.
4. Freitas J, Farricha V, Nascimento I, Borralho P, Paramés A. Rofecoxib. A possible cause of acute colitis. J Clin Gastroenterol 2002; 34: 451-3.
5. Gornet JM, Hassani Z, Modigliani R, Lémann M. Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib. Am J Gastroenterol 2002; 97: 910-14.
6. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-92.
7. Charachon A, Petit T, Lamarque D, Soulé JC. Colite aiguë hémorragique chez une malade traitée par rofécoxib associé à une auto-médication par aspirine. Gastroenerol Clin Biol 2003; 27: 511-13.
8. Bonner GF. Exacerbation of inflammatory bowel disease associated with use of celecoxib. Am J Gastroenterol 2001; 96: 1306-8.
9. Fucci JC, Kurella R. Collagenous colitis presenting with linear colonic ulcers in a patient taking a Cox-2 nonsteroidal anti-inflammatory drug. Am J Gastroenterol 2002; 97: 127.
10. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985; 40: 111-18.
11. Thiéfin G. Complications gastro-intestinales des anti-inflammatoires non stéroïdiens et de l'aspirine à faible dose. Gastroenterol Clin Biol 2003; 27: 498-510.
12. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 910-14.
13. Bjarnason I, Hayllar J, Mac Pherson A, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-47.
14. Flipo RM, Bertin P. Connaissance par les ḿdecins et les patients du risque de complications digestives des AINS. Presse Med 2003; 32: 4S48-4S52.
15. Grossman HB. Selective COX-2 inhibitors as chemopreventive and therapeutic agents. Drugs Today 2003; 39: 203-12.